It remains unclear if Tamoxifen’s modulatory role in this area is oestrogen agonistic or antagonistic, but these results give further weight to oestrogen’s relevance in MPN associated with CALR mutations. The gene discussed is CALR; the disease is myeloproliferative disorder.